SUNPHARMA

Q4 2025 Result Review....

reported a solid performance for Q4FY25 and FY25. In Q4FY25, gross sales rose by 8.5% to ₹128,156 million, with India formulation sales growing 13.6% and Global Specialty sales increasing 8.6%, now accounting for nearly 20% of total quarterly revenue. While US formulation sales dipped 2.5% to USD 464 million, Emerging Markets and Rest of World sales saw modest growth. EBITDA surged by 22.4% to ₹37,161 million, with a margin of 28.7%. Adjusted net profit for the quarter was ₹28,891 million, up 4.8%, though reported net profit declined to ₹21,499 million due to exceptional items. For FY25, Sun Pharma achieved 9.0% growth in gross sales, reaching ₹520,412 million. India formulation sales were up 13.7%, and US sales rose 3.6%. Global Specialty sales jumped 17.1% to USD 1,216 million, reinforcing the company's strategic focus on this segment. EBITDA increased by 17.3% to ₹152,717 million with a 29.0% margin, and adjusted net profit climbed 19.0% to ₹119,844 million. Chairman Dilip Shanghvi highlighted the strong domestic performance and promising pipeline in Global Specialty, including new launches like Leqselvi and Unloxcyt, signaling continued focus on specialty-driven growth.